Riomet | US Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Riomet
US Patents

PharmaCompass Sponsored Ads

Contact Supplier

Metformin

Contact Supplier

pharmacompass-1-m-2025-08-25

PharmaCompass Sponsored Ads

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

pharmacompass-2-m-2025-08-25

Riomet

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

179 API Suppliers, 57 USDMF, 42 CEP/COS, 13 JDMF, 31 EU WC, 99 KDMF, 39 NDC API, 46 Listed Suppliers, $ API Reference Price

179 API Suppliers
57 USDMF
42 CEP/COS
13 JDMF
31 EU WC
99 KDMF
39 NDC API
46 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

651 Drugs in Development

651 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1937 FDF Dossiers, 431 FDA Orange Book, 534 Europe, 134 Canada, 136 Australia, 140 South Africa, 562 Listed Dossiers

1937 FDF Dossiers
431 FDA Orange Book
534 Europe
134 Canada
136 Australia
140 South Africa
562 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;1GM, TABLET;ORAL - 2.5MG;500MG, TABLET;ORAL - 2.5MG;850MG, TABLET;ORAL - EQ 12.5MG BASE;1GM, TABLET;ORAL - EQ 12.5MG BASE;500MG, TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG, TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM, TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG, TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML, TABLET, EXTENDED RELEASE;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, SOLUTION;ORAL - 500MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 1GM, TABLET, EXTENDED RELEASE;ORAL - 500MG, TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 850MG;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE, TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE, TABLET;ORAL - 1GM;EQ 50MG BASE, TABLET;ORAL - 500MG;EQ 50MG BASE, TABLET;ORAL - 500MG;1MG, TABLET;ORAL - 500MG;2MG

TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG;EQ 5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;1GM
TABLET;ORAL - 2.5MG;500MG
TABLET;ORAL - 2.5MG;850MG
TABLET;ORAL - EQ 12.5MG BASE;1GM
TABLET;ORAL - EQ 12.5MG BASE;500MG
TABLET;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 150MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 150MG;500MG
TABLET, EXTENDED RELEASE;ORAL - 50MG;1GM
TABLET, EXTENDED RELEASE;ORAL - 50MG;500MG
TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
FOR SUSPENSION, EXTENDED RELEASE;ORAL - 500MG/5ML
TABLET, EXTENDED RELEASE;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
SOLUTION;ORAL - 500MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET, EXTENDED RELEASE;ORAL - 1GM
TABLET, EXTENDED RELEASE;ORAL - 500MG
TABLET;ORAL - 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 850MG;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 15MG BASE
TABLET, EXTENDED RELEASE;ORAL - 1GM;EQ 30MG BASE
TABLET;ORAL - 1GM;EQ 50MG BASE
TABLET;ORAL - 500MG;EQ 50MG BASE
TABLET;ORAL - 500MG;1MG
TABLET;ORAL - 500MG;2MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 8 Evonik, 7 Rochem International Inc, 23 SPI Pharma, 19 DKSH, 2 Pharm-RX Chemical, 13 Boai NKY Pharmaceuticals Ltd, 9 Gangwal Healthcare, 12 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 6 Kirsch Pharma, 1 ACG Worldwide, 12 Actylis, 3 Aeon Procare, 2 Alcedo Pharmachem, 9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 4 Ashland, 1 Avesta Pharma, 38 BASF, 1 Bioplus Life Sciences, 2 CD Formulation, 2 Clariant, 27 Corel Pharma Chem, 7 DFE Pharma, 1 Doshion Polyscience, 1 Esteem Industries, 2 Finar, 13 Gangwal Chemicals, 1 Huzhou Sunflower Pharmaceutical, 5 Ideal Cures, 5 Ingredion Pharma Solutions, 26 Kerry, 5 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 5 Lubrizol Life Science Health, 22 Microlex e.U, 2 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 11 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 35 Roquette, 14 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 2 Shijiazhuang Huaxu Pharmaceutical, 11 Sigachi Industries, 4 Silverline Chemicals, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Valens Pharmachem, 4 Vasa Pharmachem, 2 Vertellus, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

108 Fillers, Diluents & Binders, 63 Coating Systems & Additives, 57 Direct Compression, 54 Thickeners and Stabilizers, 52 Disintegrants & Superdisintegrants, 52 Controlled & Modified Release, 48 Solubilizers, 46 Granulation, 42 Taste Masking, 40 Film Formers & Plasticizers, 39 Topical, 32 Parenteral, 30 Lubricants & Glidants, 25 Chewable & Orodispersible Aids, 16 Co-Processed Excipients, 15 Emulsifying Agents, 15 Rheology Modifiers, 11 API Stability Enhancers, 8 Surfactant & Foaming Agents, 5 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

108 Fillers, Diluents & Binders
63 Coating Systems & Additives
57 Direct Compression
54 Thickeners and Stabilizers
52 Disintegrants & Superdisintegrants
52 Controlled & Modified Release
48 Solubilizers
46 Granulation
42 Taste Masking
40 Film Formers & Plasticizers
39 Topical
32 Parenteral
30 Lubricants & Glidants
25 Chewable & Orodispersible Aids
16 Co-Processed Excipients
15 Emulsifying Agents
15 Rheology Modifiers
11 API Stability Enhancers
8 Surfactant & Foaming Agents
5 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 374 News #PharmaBuzz

1 Data Compilation #PharmaFlow
374 News #PharmaBuzz

GLOBAL SALES INFORMATION

96 US Medicaid Prescriptions, 494 Regulatory FDF Prices, 58 Annual Reports

96 US Medicaid Prescriptions
494 Regulatory FDF Prices
58 Annual Reports

MARKET PLACE

92 APIs, 51 FDF Dossiers

92 APIs
51 FDF Dossiers

PATENTS & EXCLUSIVITIES

619 US Patents, 54 US Exclusivities, 156 Health Canada Patents

619 US Patents
54 US Exclusivities
156 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 1 USP, 17 Others

3 EDQM
1 USP
17 Others

ANALYTICAL

2 BioAnalytical Methods, 1 Analytical Methods

2 BioAnalytical Methods
1 Analytical Methods

$ API Ref.Price (USD/KG) : 4 Xls

Filters

Reset all filters

Filters

FILTER :

filter Applicant Reset all filters

619 All

01 100ASTRAZENECA AB

02 359BOEHRINGER INGELHEIM

03 116JANSSEN PHARMS

04 26MSD SUB MERCK

05 1SANTARUS INC

06 1SUN PHARM

07 16TAKEDA PHARMS USA

filter Patent Number Reset all filters

619 All

01 510022379*PED

02 1210258637*PED

03 410596120*PED

04 410610489*PED

05 310973827*PED

06 1211090323*PED

07 96515117

08 96515117*PED

09 57326708

10 57326708*PED

11 97407955

12 97407955*PED

13 127579449

14 127579449*PED

15 127713938

16 127713938*PED

17 17780987

18 27785627

19 27807689

20 97919598

21 97919598*PED

22 247943582

23 87943582*PED

24 87943788

25 87943788*PED

26 27959946

27 48080580

28 28173663

29 248222219

30 88222219*PED

31 28288539

32 28414921

33 98501698

34 248513202

35 48551957

36 78628799

37 58673927

38 58685934

39 48716251

40 910022379

41 1210258637

42 410406172

43 1610596120

44 410610489

45 310973827

46 1211090323

47 311564886

48 411576894

49 811666590

50 411813275

51 2411833166

52 511911388

53 1212115179

54 812263153

55 912364700

56 28414921*PED

57 98501698*PED

58 88513202*PED

59 48551957*PED

60 58673927*PED

61 58685934*PED

62 48716251*PED

63 38846695

64 38846695*PED

65 98883805

66 98883805*PED

67 28900638

68 29101660

69 99155705

70 59155705*PED

71 29173859

72 29173859*PED

73 49308204

74 29320714

75 39339472

76 99415016

77 59415016*PED

78 49439902

79 49555001

80 29555001*PED

81 99616028

82 99616028*PED

83 169949997

84 89949997*PED

85 89949998

86 89949998*PED

87 19962336

filter API Patent Reset all filters

619 All

01 121Y

02 498Blank

filter FDF Patent Reset all filters

619 All

01 222Y

02 397Blank

filter Expiration Date Reset all filters

619 All

01 22025-03-15

02 12025-03-23

03 242025-04-11

04 92025-05-02

05 22025-06-24

06 102025-07-13

07 92025-10-04

08 82025-10-11

09 92025-11-02

10 92025-11-26

11 92026-04-04

12 92026-05-26

13 42026-07-31

14 52026-11-24

15 22027-01-22

16 122027-04-15

17 72027-05-04

18 52027-05-24

19 92027-06-20

20 82027-07-14

21 122027-10-15

22 72027-11-04

23 242027-12-03

24 92027-12-20

25 82028-01-14

26 42028-03-21

27 82028-06-03

28 22028-06-27

29 22028-07-21

30 122028-08-01

31 42028-09-21

32 22029-01-21

33 122029-02-01

34 22029-02-03

35 242029-02-26

36 212029-04-02

37 22029-05-24

38 82029-08-26

39 132029-10-02

40 42029-10-14

41 92029-12-16

42 122030-02-11

43 52030-04-10

44 42030-04-14

45 92030-05-21

46 52030-05-26

47 32030-06-04

48 42030-06-15

49 92030-06-16

50 42030-07-06

51 42030-07-13

52 42030-09-30

53 82030-10-21

54 92030-11-12

55 52030-11-21

56 52030-11-26

57 32030-12-04

58 42031-03-30

59 92031-05-12

60 192032-03-07

61 42032-09-07

62 42033-03-06

63 22033-09-06

64 682034-04-03

65 162034-05-17

66 82034-06-11

67 242034-10-03

68 82034-11-17

69 82034-12-11

70 12035-05-01

71 92037-06-08

Granules Metformin

Product Main Page

01

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

04

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

05

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 205649

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

06

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2030-05-26

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

US Patent Number : 8685934

Drug Substance Claim :

Drug Product Claim :

Application Number : 205649

Patent Use Code : U-1522

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2030-05-26

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

07

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

08

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2025-10-04

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 6515117

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2025-10-04

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

09

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

10

ASTRAZENECA AB

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

Process Development

Not Confirmed

ASTRAZENECA AB

Process Development

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2027-06-20

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

US Patent Number : 8501698

Drug Substance Claim :

Drug Product Claim : Y

Application Number : 210874

Patent Use Code : U-493

Delist Requested :

Patent Use Description : TREATMENT OF TYPE 2 DI...

Patent Expiration Date : 2027-06-20

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

1
2
3
Last

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!